case_images: PMC10784753_01
case_images: Clinical characteristics of our patient with anti-IgLON5 disease. Upper part of A shows the symptoms; middle shows the time and the treatment, and lower part shows the examination. Only the abnormal psychiatric behaviors were improved with steroid, IVIg, and olanzapine treatment. The left part of B shows the immunoactivity of the anti-IgLON5 antibodies in CSF (1:320), and the right part shows anti-IgLON5 antibodies in serum (1:100) (original magnification x 200).
case_images: CCR3-12-e8310-g001.jpg
case_images: PMC10784753_01_CCR3-12-e8310-g001.jpg
case_images: ccr38310-fig-0001
case_images: Moreover, the bulbar dysarthria, oculomotor dysfunction (restriction of vertical and horizontal gaze), and mild cognitive impairment (Mini Mental State Examination was 21) appeared 4 months ago (Figure 1A). Only the anti-IgLON5 antibody test was positive in both CSF and serum (1:320 and 1:100, respectively; Figure 1B). Including our patient, 19 cases were eligible for our review (Table 1; Data S1, Figure S1).